!
We use cookies to help provide you with a better service. You can change your cookie settings at any time. Otherwise, we will assume you're OK to continue.
×
Menu
Close
Our portfolioFoundationOne CDxFoundationOne LiquidFoundationOne Heme

 

 

Our portfolio
 

High-quality portfolio

A high-quality portfolio of services for patients in diverse clinical situations

Foundation Medicine’s high-quality portfolio of comprehensive genomic profiling services helps healthcare professionals to optimise and personalise treatment strategies for patients in diverse clinical situations:1–4
EXPLORE EXPLORE EXPLORE Solid tumour Haematologic malignancy and sarcoma What type of tumour does your patient have? Tissue sample Blood sample Tissue-based test for solid tumours 1,2 EXPLORE Tissue-based test for solid tumours 1,2 Liquid biopsy test for solid tumours 3 EXPLORE Liquid biopsy test for solid tumours 3 Test for haematological malignancies and sarcomas 4 EXPLORE Test for haematological malignancies and sarcomas 4
All our services use our leading comprehensive genomic profiling approach to identify clinically relevant alterations and potentially expand treatment options

All of Foundation Medicine's services use our leading comprehensive genomic profiling approach, wich broadly analyses the tumour genome to identify clinically relevant alterations and potentially expands patients' treatment options.5-10
Learn more about comprehensive genomic profilling
Genomic database

 

As our understanding of cancer evolves, so do our tests

Our continuously growing genomic database currently includes over 200,000 genomic profiles in over 150 common and rare tumour subtypes. Advanced bioinformatics interpret the data, including rare and complex alterations, to generate powerful insights.11 Our tests are constantly evolving to capture the most clinically relevant genomic alterations so you stay up-to-date and the latest treatment options can be considered.1,6

Our growing database includes 200,000+ genomic profiles, allowing our tests to constantly evolve so we can provide the most clinically relevant insights
References
  1. FoundationOne®CDx Technical Specifications, 2018. Available at: www.rochefoundationmedicine.com/f1cdxtech (Accessed March 2019).
  2. FoundationOne®CDx FDA Approval, 2017. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019a.pdf (Accessed March 2019).
  3. FoundationOne®Liquid Technical Specifications, 2018. Available at: https://www.foundationmedicine.com/genomic-testing/foundation-one-liquid (Accessed March 2019).
  4. FoundationOne®Heme Technical Specifications, 2017. Available at: www.foundationmedicine.com/genomic-testing/foundation-one-heme (Accessed March 2019).
  5. Drilon A et al. Clin Cancer Res 2015; 21: 3631–3639.
  6. Frampton GM et al. Nat Biotechnol 2013; 31: 1023–1031.
  7. Rankin A et al. Oncologist 2016; 21: 1306–1314.
  8. Ross JS et al. Cancer 2016; 122: 2654–2662.
  9. Suh JH et al. Oncologist 2016; 21: 684–691.
  10. Hirshfield KM et al. Oncologist 2016; 21: 1315–1325.
  11. Foundation Insights. Available at: https://www.foundationmedicine.com/insights-and-trials/foundation-insights (Accessed March 2019).